Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359682 | 1.00 | CYP3A4 (0.45) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL15918823 | 1.00 | CYP3A4 (0.45) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL5133861 | 0.97 | CYP3A4 (0.45) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL14701472 | 0.92 | CYP3A4 (0.45) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL14701450 | 0.87 | ALDH1A1 (0.63) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL13508825 | 0.86 | ALDH1A1 (0.52) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL13077184 | 0.86 | CYP3A4 (0.56) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL8240944 | 0.86 | CYP3A4 (0.56) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL8249233 | 0.86 | CYP3A4 (0.56) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL13508834 | 0.86 | CYP3A4 (0.56) | CYP3A4MAPK1ALDH1A1SMN1; SMN2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556140-B2 | Approach for synthesis of catechins | SPHAERA PHARMA PVT. LTD. (IN) | 2017-01-31 | — | — | US | disclosed |
| US-20150368223-A1 | NOVEL APPROACH FOR SYNTHESIS OF CATECHINS | EPIRIUM BIO INC. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368223-A1 | NOVEL APPROACH FOR SYNTHESIS OF CATECHINS | NQO1, COMT, NNMT | CYP3A4 144/4885MAPK1 2894/4885ALDH1A1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.